Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Non-Current Deferred Tax Liability (2016 - 2025)

Sanofi (SNY) has disclosed Non-Current Deferred Tax Liability for 11 consecutive years, with $1.9 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 16.21% to $1.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, down 16.21% year-over-year, with the annual reading at $1.9 billion for FY2025, 19.71% down from the prior year.
  • Non-Current Deferred Tax Liability hit $1.9 billion in Q4 2025 for Sanofi, down from $2.3 billion in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.3 billion in Q4 2024 to a low of $1.8 billion in Q4 2021.
  • Historically, Non-Current Deferred Tax Liability has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2025.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: grew 15.84% in 2024 and later fell 16.21% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $1.8 billion in 2021, then rose by 1.54% to $1.9 billion in 2022, then grew by 6.38% to $2.0 billion in 2023, then rose by 15.84% to $2.3 billion in 2024, then decreased by 16.21% to $1.9 billion in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for SNY at $1.9 billion in Q4 2025, $2.3 billion in Q4 2024, and $2.0 billion in Q4 2023.